If the role we propose for EC injury in PASC, whether central or simply an important contributory factor, parallels its dominance in the pathology of acute COVID-19, at least some of the interventions utilized in the latter, including dexamethasone, baricitinib, anticomplement (C3, C5, MASP-2) agents, and defibrotide (20, 22, 37, 38, 61, 135, 136), might be evaluated in rodent models for acute SARS-CoV-2 infection (106, 137), then tested clinically (Figure 3). This evidence concerns the gene MASP2 and COVID-19.